Avantor (AVTR) vs Bio-Rad Laboratories (BIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bio-Rad Laboratories (BIO) has outperformed Avantor (AVTR) over the past year, gaining 24.1% versus a gain of 14.0%. Over five years, BIO leads with a -49.0% price change compared with -60.0% for AVTR. Avantor is the larger company by market cap ($10.38 billion vs $9.84 billion), about 1.1 times the size, while Bio-Rad Laboratories is growing revenue faster (+0.7% vs -3.4%).
On valuation, Avantor trades at a lower forward P/E (17.5x vs 37.1x for Bio-Rad Laboratories). Bio-Rad Laboratories converts more of its revenue into profit, with a net margin of 29.4% versus -8.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVTR | BIO |
|---|---|---|
| Share price | $15.35 | $367.92 |
| Market cap | $10.38B | $9.84B |
| 1-day change | -0.52% | -0.25% |
| YTD return | +33.94% | +21.43% |
| 1-year return | +13.96% | +24.08% |
| 5-year return | -59.97% | -49.00% |
| P/E ratio (TTM) | — | 46.75 |
| Forward P/E | 17.48 | 37.10 |
| EPS (TTM) | $-0.84 | $7.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $6.55B | $2.58B |
| Revenue growth (YoY) | -3.41% | +0.65% |
| Net income (latest FY) | $-530.20M | $759.90M |
| Gross margin | 32.65% | 51.87% |
| Operating margin | -3.76% | 1.83% |
| Net margin | -8.09% | 29.42% |
| 52-week high | $16.38 | $396.23 |
| 52-week low | $7.27 | $236.73 |
| Distance from 52-week high | -6.26% | -7.14% |
| Analyst consensus | hold | hold |
| Avg. price target upside | -3.71% | -10.76% |
| Average volume | 9.45M | 277.32K |
| Shares outstanding | 676.36M | 21.68M |
| Employees | 13,500 | 7,450 |
| Sector | Industrials | Industrials |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Laboratory Analytical Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIO has outperformed AVTR by 10.1 percentage points over the past year.
- Bio-Rad Laboratories is more profitable, keeping 29.4 cents of every revenue dollar as net income versus -8.1 cents for Avantor.
About Avantor
AVTR stock →Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa.
Industrials · Biotechnology: Laboratory Analytical Instruments · 13,500 employees
About Bio-Rad Laboratories
BIO stock →Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally.
Industrials · Biotechnology: Laboratory Analytical Instruments · 7,450 employees
AVTR vs BIO FAQ
Which is bigger, Avantor or Bio-Rad Laboratories?
Avantor (AVTR) is larger, with a market capitalization of $10.38B compared with $9.84B for Bio-Rad Laboratories (BIO).
Which stock has performed better over the past year, AVTR or BIO?
BIO returned +24.08% over the past 12 months, compared with +13.96% for AVTR (price return, excluding dividends). Past performance does not predict future results.
Are Avantor and Bio-Rad Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Laboratory Analytical Instruments industry within the Industrials sector.